CAPR - Capricor Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.70
-0.08 (-4.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.78
Open1.82
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.67 - 1.85
52 Week Range0.63 - 4.25
Volume290,412
Avg. Volume741,490
Market Cap43.707M
Beta-0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateMar 13, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Trade prices are not sourced from all markets
  • GlobeNewswire19 hours ago

    Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies

    LOS ANGELES, Jan. 16, 2018-- Capricor Therapeutics announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies ...

  • GlobeNewswirelast month

    Market Trends Toward New Normal in Lockheed Martin, Silver Spring Networks, Capricor Therapeutics, Tupperware Brands, Eaton Vance, and Marcus & Millichap — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Dec. 18, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lockheed ...

  • Capital Cubelast month

    ETFs with exposure to Capricor Therapeutics, Inc. : December 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Capricor Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CAPR-US. Comparing the performance and risk of Capricor Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology
    PR Newswirelast month

    Capricor Therapeutics Announces Issuance of Key U.S. Patent on Exosome Technology

    LOS ANGELES, Dec. 13, 2017 /PRNewswire/ -- Capricor Therapeutics (CAPR) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent  9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes. The therapeutic prospect of CAP-2003 in hypoplastic left heart syndrome (HLHS) is supported by preclinical studies in which this candidate was evaluated in a model of pressure-induced right ventricular dysfunction, representative of the disease present in many single ventricle congenital heart conditions such as HLHS.

  • How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?
    Simply Wall St.last month

    How Does Capricor Therapeutics Inc’s (CAPR) EPS Growth Stack Up Against Industry Performance?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • ACCESSWIRE2 months ago

    Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy

    Stock Monitor: Cleveland BioLabs Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Capricor Therapeutics, Inc. (NASDAQ: CAPR ), which is readily ...

  • Capital Cube2 months ago

    ETFs with exposure to Capricor Therapeutics, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Capricor Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CAPR-US. Comparing the performance and risk of Capricor Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capricor Therapeutics Inc (CAPR) Shares Soar on Back of FDA Investigational New Drug Clearance
    SmarterAnalyst2 months ago

    Capricor Therapeutics Inc (CAPR) Shares Soar on Back of FDA Investigational New Drug Clearance

    Capricor Therapeutics Inc (NASDAQ:CAPR) is on the move. The drug maker’s stock price spiked nearly 8% today, following the news that the company received U.S. FDA clearance for the Investigational New Drug application (IND) for CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses.

  • MarketWatch2 months ago

    Capricor Therapeutics stock rises 18% on FDA clearance for DMD clinical trial

    Capricor Therapeutics Inc. shares rose nearly 18% in extremely heavy Wednesday morning trade after the company said the Food and Drug Administration has cleared its Duchenne muscular dystrophy therapy ...

  • Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube2 months ago

    Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Capricor Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Capricor Therapeutics, Inc. – Cytokinetics, Incorporated, Cytori Therapeutics, Inc., Caladrius Biosciences, Inc., ARCA biopharma, Inc., Johnson & Johnson, Eiger BioPharmaceuticals, Inc., Portola Pharmaceuticals, Inc., BioTime, Inc., Palatin Technologies, ... Read more (Read more...)

  • Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
    PR Newswire2 months ago

    Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002

    LOS ANGELES, Nov. 29, 2017 /PRNewswire/ -- Capricor Therapeutics (CAPR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy, a fatal genetic disorder for which there are limited treatment options. This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses.

  • Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference
    PR Newswire2 months ago

    Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference

    LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- Capricor Therapeutics (CAPR) announced that Linda Marbán, Ph.D., president and CEO, will present at the Piper Jaffray Healthcare Conference in New York on Wednesday, November 29, 2017 at 11:50 a.m. ET. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and Capricor Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 16, 2017 / Shares of Acorda were bleeding heavily in Wednesday trading after the company announced that five patients had died during clinical trials of its Parkinson's ...

  • Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy
    PR Newswire2 months ago

    Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor's Investigational Cell Therapy

    ANAHEIM, Calif., Nov. 15, 2017 /PRNewswire/ -- Boys and young men in advanced stages of Duchenne muscular dystrophy experienced significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following treatment with CAP-1002, the lead investigational therapy under development at Capricor Therapeutics (CAPR). Dr. Victor, who is the associate director for clinical research at the Cedars-Sinai Heart Institute and a lead investigator for the HOPE trial, reported that those treated with CAP-1002 had improvement in cardiac muscle function and reduction in cardiac scarring that were statistically-significant in comparison to the control group, according to a pre-specified analysis.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Leucadia National, Matador Resources, Bemis Company, Capricor Therapeutics, IZEA, and Comcast – Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 13, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leucadia ...

  • Associated Press2 months ago

    Capricor reports 3Q loss

    The Beverly Hills, California-based company said it had a loss of 12 cents per share. The biotechnology company posted revenue of $313,300 in the period. Its adjusted revenue was $313,000. In the final ...

  • Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program
    PR Newswire2 months ago

    Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program

    12-Month Results from HOPE Clinical Trial to be Presented Next Week at AHA Potential Registration Trial Planned to Initiate in the First Quarter of 2018 Company to Host Conference Call and Webcast Today ...

  • Capricor Therapeutics Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8
    PR Newswire2 months ago

    Capricor Therapeutics Third Quarter 2017 Update Webcast and Conference Call Scheduled for Wednesday, November 8

    LOS ANGELES, Nov. 1, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, will report third quarter 2017 financial results shortly after the NASDAQ market close on Wednesday, November 8, 2017. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an "off-the-shelf" cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

  • Capital Cube3 months ago

    ETFs with exposure to Capricor Therapeutics, Inc. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Capricor Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CAPR-US. Comparing the performance and risk of Capricor Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ACCESSWIRE3 months ago

    Corporate News Blog - Capricor to Present 12-Month Results From HOPE-1 Trial in Duchenne Muscular Dystrophy at AHA Scientific Sessions 2017

    Research Desk Line-up: Vertex Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Capricor ...

  • Capricor Therapeutics Inc (CAPR) Shares Climb Ahead of the American Heart Association (AHA) Scientific Sessions 2017
    SmarterAnalyst3 months ago

    Capricor Therapeutics Inc (CAPR) Shares Climb Ahead of the American Heart Association (AHA) Scientific Sessions 2017

    US-based biotechnology firm Capricor Therapeutics Inc (NASDAQ:CAPR) announced that the American Heart Association (AHA) Scientific Sessions 2017 has accepted for presentation at a late-breaking session the 12-month results from the company's HOPE-1 clinical trial of its lead investigational product, CAP-1002, in boys and young men in advanced stages of Duchenne muscular dystrophy. Ronald G. Victor, M.D., associate director for clinical research at the Cedars-Sinai Heart Institute and an investigator for the HOPE-1 Trial, will present the results during a session entitled "Innovative Therapies and Novel Applications," which will begin at 9 a.m. on Nov. 15 at the Anaheim Convention Center. HOPE-1 is a randomized Phase I/II 12-month clinical trial that evaluated a single dose of CAP-1002, a cell-based therapeutic candidate, in 25 boys and young men in advanced stages of Duchenne muscular dystrophy, a rare, life-threatening genetic disorder.

  • Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session
    PR Newswire3 months ago

    Capricor Announces 12-Month Results from HOPE-1 Trial in Duchenne Muscular Dystrophy to be Presented at AHA Late-Breaking Session

    LOS ANGELES, Oct. 25, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (CAPR) today announced that the American Heart Association (AHA) Scientific Sessions 2017 has accepted for presentation at a late-breaking session the 12-month results from the company's HOPE-1 clinical trial of its lead investigational product, CAP-1002, in boys and young men in advanced stages of Duchenne muscular dystrophy. Ronald G. Victor, M.D., associate director for clinical research at the Cedars-Sinai Heart Institute and an investigator for the HOPE-1 Trial, will present the results during a session entitled "Innovative Therapies and Novel Applications," which will begin at 9 a.m. on Nov. 15 at the Anaheim Convention Center. HOPE-1 is a randomized Phase I/II 12-month clinical trial that evaluated a single dose of CAP-1002, a cell-based therapeutic candidate, in 25 boys and young men in advanced stages of Duchenne muscular dystrophy, a rare, life-threatening genetic disorder.

  • Capital Cube3 months ago

    ETFs with exposure to Capricor Therapeutics, Inc. : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Capricor Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CAPR-US. Comparing the performance and risk of Capricor Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
    PR Newswire3 months ago

    Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy

    CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), whose mechanism of action is immunomodulatory and anti-fibrotic. CDCs have been shown to generate new muscle cells in preclinical models.

  • Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
    PR Newswire3 months ago

    Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress

    DMD is a rare, life-threatening genetic disorder for which treatment options are limited. The late breaking abstract and results presented at the late breaking poster session describe the first six months of follow-up data from the randomized 12-month Phase I/II HOPE clinical trial of CAP-1002. CAP-1002 is a cell-based therapeutic candidate and consists of allogeneic cardiosphere-derived cells, whose mechanism of action is immunomodulatory and anti-fibrotic, and which have been shown to generate new muscle cells in preclinical models.